Redsiway summary clinical trial results released to focus on new developments in new crown therapy.

At present, the 2019 coronavirus disease (COVID-19) pandemic caused by Severe Acute Respiratory Syndrome (SARS-CoV-2) has become a global crisis.
October 1, White House adviser Hope Hicks tested positive for the new coronavirus, and then both Trump and his wife, Melania, tested positive for isolation and rehabilitation.
, one of the drugs used in Trump's treatment, was unveiled by the White House's presidential doctor.
Gilead Sciences announces the results of the new coronary clinical trial of Redsiway Therapeutics October 10, Gilead Sciences published a weighty article in NEJM reporting on the results of a summary clinical trial of Redsiway's treatment COVID-19.
As the most comprehensive clinical trial to date on Redsiway, the ACTT-1 Study (NCT04280705) is a double-blind, randomized, controlled clinical trial in which 1,062 hospitalized COVID-19 patients were recruited worldwide and given 10 days of Redsiway treatment.
clinical trials found that the medium recovery time for patients receiving Redsyve was 10 days, and the medium time for patients treated with a placebo was 15 days .
, Redsyve has a significant effect on accelerating the recovery of oxygen-absorbing patients.
if the differences between Redsyve and placebo were evaluated on an 8-category scale, the study found that on the 15th day, Redsyves significantly improved clinical performance in patients.
in terms of security, there was no significant difference in the rate of adverse events between the two groups of subjects.
is noteworthy that the NIH has updated its COVID-19 treatment guidelines, based on the latest results from the ACTT-1 study.
For inpatients, the need for oxygen absorption is given to Rhedsiwe or Redsiwe co-site symisson, and for patients requiring high-flow oxygen absorption, mechanical aeration and ECMO, Rhedsiwe co-site symisson is required.
Redsyvir's mechanism of effect for new coronary therapy, the new coronavirus RNA-dependent RNA polymerase (RdRp), is a key component of the coronavirus replication/transcription mechanism, which catalyzes the synthesis of viral RNA, with RNA polymerase as the core, and coronaviruses self-replicate using other cofactors such as nsp7, nsp8, etc.
GS-5734, developed by Gilead Sciences, is a drug prelude to adenine-like substances that is reported to clinically inhibit the proliferation of 2019-nCoV and has the potential to treat patients.
earlier, a review of COVID-19 treatment options published online by Nature Reviews Drug Discovery noted that Redsyvir, a adenine-like similar, can be used by RdRP enzymes to synthesize RNA strands, blocking the synthesis of viral RNA in a variety of RNA viruses, including human coronaviruses.
In mid-March this year, a team of researchers from several chinese and foreign universities successfully analyzed the structure of the new coronavirus RNA-dependent RNA polymerase (RdRp) internationally, and mapped the three-dimensional structure of RdRpase, entitled "Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target" was published on the biomedical preprint platform.
as a major potential target for antiviral drugs such as Redsivir, the analysis of the structure of RdRp enzymes can help scientists overcome the challenge of inhibiting the replication of new coronaviruses.
may this year, a study entitled "Structural basis for resion of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir" provided redsivir's fight against the new coronavirus. High-level evidence that the composite structure of Redsyvir under the frozen electroscope with the new coronavirus polymerase shows that part of the double-stranded RNA template is inserted into the central channel of RdRp, and Redsyvir is in the first replication base pair to be co-priced into the lead chain and terminates the chain extension.
Recent clinical advances in new crown vaccines and therapeutic drugs, in addition to the aggregate clinical trial results of Redsyvir's treatment of COVID-19, have recent advances in clinical studies of vaccines and therapeutic drugs for new coronaviruses, which are noteworthy.
October 1, the EMA launched a rolling review of AstraZeneta/Oxford University's new crown vaccine, AZD1222.
October 6, Pfizer/BioNTech submitted a rolling application for BNT162b2 for the new crown vaccine to the EMA.
Currently, phase III clinical trials in more than 120 centers around the world, with approximately 37 million patients in the group, and on the same day, Vir Botechnology/GSK announced that the COMET-ICE study for early neo crown patients with a higher risk of hospitalization in VIR-7831 and antibody therapy had been extended to Phase III globally, incorporating more centers in North America, South America and Europe into a group of 1,300 patients.
October 7, Lilly announced the latest phase of a BLAZE-1 study that includes LY-CoV555 and LY-CoV016 for newly diagnosed patients with light to moderate COVID-19 Data, combined therapy significantly reduced the viral load on day 11 and reached the primary endpoint of clinical studies, while Lilly submitted to the FDA an emergency use authorization application for LY-CoV555 single-drug for high-risk newly diagnosed mild to moderate new crown patients.
October 8, Regenerative Meta announced that it had submitted to the FDA an application for emergency use authorization for the treatment of new crown patients using resynthetic antibody combination therapy REGEN-COV2.
: Small pills, pharmaceutical industry practitioners, text porters from the media age, focusing on the pharmaceutical industry in the cold and warm.
.